NEW YORK CITY — The recent awarding of the 13th annual Ross Prize in Molecular Medicine to Carl June, MD, and Michel Sadelain, MD, PhD, underscores the critical role of perseverance in advancing CAR T-cell therapy for cancer treatment. This recognition, presented at a ceremony in midtown Manhattan, celebrates the transformative impact of their pioneering research on immunotherapy, a field that has evolved significantly over the last decade.
The Ross Prize, established in 2013 through the Feinstein Institutes, honors biomedical scientists whose innovations have reshaped medical practices. June and Sadelain’s work exemplifies the long-term commitment required to achieve breakthroughs in cancer therapy, particularly as they navigated numerous setbacks before achieving regulatory approval for CAR T therapies.
Both honorees emphasized that the journey to success in scientific research is often fraught with challenges, requiring not just innovation but also a steadfast commitment to overcoming obstacles. Their experiences illustrate a paradigm shift in the perception of immunotherapy, paving the way for future advancements in both blood cancers and solid tumors. As the field continues to evolve, the implications of their work extend beyond oncology, potentially impacting treatments for autoimmune diseases and beyond.
Open the full market picture for your next decision →
